Allosteric modulation of GSK-3β as a new therapeutic approach in limb girdle muscular dystrophy R1 calpain 3-related

18 p.-8 fig.-1 tab.Limb-girdle muscular dystrophy R1 calpain 3-related (LGMDR1) is an autosomal recessive muscular dystrophy produced by mutations in the CAPN3 gene. It is a rare disease and there is no cure or treatment for the disease while the pathophysiological mechanism by which the absence of calpain 3 provokes the dystrophy in muscles is not clear. However, key proteins implicated in Wnt and mTOR signaling pathways, which regulate muscle homeostasis, showed a considerable reduction in their expression and in their phosphorylation in LGMDR1 patients’ muscles. Finally, the administration of tideglusib and VP0.7, ATP non-competitive inhibitors of glycogen synthase kinase 3β (GSK-3β), restore the expression and phosphorylation of these proteins in LGMDR1 cells, opening the possibility of their use as therapeutic optionsThis work was financed through the grants received from the Health Research Fund (PI16/01325, PI17/01841 and DTS19/00061) of the Spanish Ministry of Economy and Competitiveness and the European Union (ERDF) and it was in part supported by the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED: CB06/05/1126 to A.R., G.G., A.V., L.C.-F., A.L.d.M. and A.S. and CB18/05/00040 to A.M. and V.P.), Carlos III Health Institute and by GENE (Association of Neuromuscular diseases of Gipuzkoa). A.R. was supported by the predoctoral fellowship given by the department of Education, Universities and Research of the Basque Government (PRE-2016-1-0382).Peer reviewe